Quantcast

Congressional Committee Concerned Over J&J Recall

June 11, 2010

A spokeswoman said on Friday that a U.S. Congressional committee investigating the recent recall of Johnson & Johnson’s children’s medicine is “deeply concerned” about the manufacturer’s cooperation.

The House Committee on Oversight and Government Reform has been investigating J&J’s widespread recall announced in April of its Tylenol, Motrin, Benadryl and Zyrtec products for infants and children.  The committee held a hearing on the issue last month.

“The committee is deeply concerned about Johnson & Johnson’s response and cooperation with our investigation,” committee spokeswoman Jenny Rosenberg told Reuters news.

The New York Times reported on Friday that U.S. Representative Edolphus Towns, the house committee’s chairman, said J&J had used delaying tactics in its dealings with the committee and in some instances had provided misinformation.

The Times said J&J denied the accusations.

According to the report, Towns said the conduct might compel the committee to take more aggressive action as it looks into drug quality and safety issues raised by the recall.

“We are not getting the kind of information and cooperation” that he would like, the paper quoted Towns as saying in an interview.

Rosenberg said Towns’ comments in the report were accurate.

J&J spokeswoman Bonnie Jacobs told the paper that the company had been “very cooperative with the committee.”  According to the report, she said J&J has provided the committee with about 20,000 pages of documents, made its executives available for interviews and answered queries in a timely manner.

Reuters reported that Jacobs said she was quoted accurately on the story.

On the Net:




comments powered by Disqus